InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.60
(
-0.12%
)
Bitcoin
65,410.55
(
0.68%
)
Post# of 647605
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Volcano

Send PM Follow Ignore
Followers 495
Posts 32125
Boards Moderated 0
Alias Born 03/12/2014

Volcano

Re: None

Thursday, 04/25/2024 5:02:20 PM

Thursday, April 25, 2024 5:02:20 PM

Post# of 647605
NKGN

SNK01 was found to reduce and/or improve levels of pTau, amyloid AB42/40, and alpha-synuclein protein biomarkers suggesting that it could have utility far beyond Alzheimer's. 90% of patients enrolled in the proof-of-concept Phase 1 had improved or stable cognitive function at week 11 using the composite ADCOMS score.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up